Cantor Fitzgerald Predicts VYGR FY2024 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Voyager Therapeutics in a report released on Monday, January 13th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will earn ($0.98) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $5.73 target price on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.89) per share.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.29. The business had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the previous year, the firm earned ($0.59) EPS.

Other research analysts also recently issued research reports about the stock. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Citigroup initiated coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price objective on the stock. Leerink Partners assumed coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective on the stock. Wedbush initiated coverage on shares of Voyager Therapeutics in a research report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price objective for the company. Finally, StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $15.97.

Voyager Therapeutics Price Performance

VYGR opened at $5.05 on Tuesday. Voyager Therapeutics has a 1 year low of $5.03 and a 1 year high of $10.66. The business has a fifty day simple moving average of $6.07 and a 200 day simple moving average of $6.79. The company has a market capitalization of $275.86 million, a PE ratio of 7.11 and a beta of 0.93.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of VYGR. China Universal Asset Management Co. Ltd. raised its position in shares of Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after acquiring an additional 4,098 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Voyager Therapeutics in the third quarter valued at approximately $74,000. Victory Capital Management Inc. grew its position in Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after acquiring an additional 1,630 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in Voyager Therapeutics during the 2nd quarter valued at about $128,000. Finally, Verition Fund Management LLC bought a new position in shares of Voyager Therapeutics during the third quarter valued at approximately $216,000. 48.03% of the stock is currently owned by institutional investors.

Insider Transactions at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 4.53% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.